Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hepion Pharmaceuticals Inc HEPA

Healthcare
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address... see more

Recent & Breaking News (NDAQ:HEPA)

Hepion Pharmaceuticals Announces Publication in Expert Opinion on Investigational Drugs

Accesswire January 6, 2020

Hepion Pharmaceuticals Successfully Advances to Next Dosing Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

Accesswire December 10, 2019

Hepion Pharmaceuticals to Present Clinical and Scientific Updates at HEP DART 2019

Accesswire December 9, 2019

Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments

Accesswire December 3, 2019

Hepion Pharmaceuticals to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

Accesswire December 3, 2019

Hepion Pharmaceuticals' CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease

Accesswire November 20, 2019

Hepion Pharmaceuticals to Present at The Liver Meeting(R) 2019

Accesswire November 7, 2019

Hepion Pharmaceuticals' CRV431 Reduces Liver Fibrosis in a Western Diet Model of NASH

Accesswire November 7, 2019

Hepion Pharmaceuticals to Present on CRV431 at the 3rd Annual NASH Summit

Accesswire October 23, 2019

Hepion Pharmaceuticals Announces Publication of Data Highlighting CRV431's Potential as a Treatment for Chronic Liver Diseases

Accesswire October 16, 2019

World-Renowned Liver Disease Expert, Dr. Stephen Harrison, Joins Hepion Pharmaceuticals as Consultant Medical Director

Accesswire October 10, 2019

AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer

GlobeNewswire October 10, 2019

Hepion Pharmaceuticals Strengthens Management Team with Three Key Promotions

Accesswire October 3, 2019

Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference

GlobeNewswire September 4, 2019

Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

GlobeNewswire September 3, 2019

Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431

GlobeNewswire August 14, 2019

Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board

GlobeNewswire August 7, 2019

Hepion Pharmaceuticals Announces Research Partnership with Applied Pharmaceutical Innovation, Faculty of Pharmacy & Pharmaceutical Sciences at University of Alberta

GlobeNewswire July 31, 2019

Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH

GlobeNewswire July 29, 2019

ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to "HEPA"

GlobeNewswire July 22, 2019